ArticleAnnals of nuclear medicine2026
Evolving trends in yttrium-90 radioembolization research: a comprehensive bibliometric study.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveYttrium-90 (Y-90) radioembolization has become a key therapeutic option for liver malignancies and is expanding into extrahepatic applications. This study aims to provide a Y-90-focused, field-wide bibliometric map that links global research trends to practice-defining contexts and explicitly contrasts glass versus resin microspheres and primary versus metastatic liver disease. MATERIALS AND
methodsThe Web of Science Core Collection was queried for articles and reviews from 2005 to 12 July 2024. CiteSpace, VOSviewer, and Bibliometrix were employed to visualize annual output, co-authorship and institutional networks, reference co-citation backbones, and keyword clusters and bursts. Studies were narratively classified by microsphere type (glass vs resin) and disease context (hepatocellular carcinoma vs metastatic liver cancers).
resultsThe study analyzed 2,002 publications, revealing an annual growth rate of 8%. Scientific production and collaboration were concentrated in North America and Western Europe. The co-citation core was dominated by foundational hepatocellular carcinoma outcomes and international recommendations. In sub analyses, glass microsphere literature was clustered with hepatocellular carcinoma, and segmentectomy; resin microsphere literature was concentrated in colorectal liver metastases within randomized or combination regimens. Primary-disease corpora were shown to emphasize survival and transplant pathways, whereas metastatic corpora focused on local control within multimodality care.
conclusionThis analysis underscores the significant growth and thematic shifts in Y-90 research, while highlighting gaps such as the need for randomized trials and long-term outcome studies. Addressing these gaps will advance Y-90 radioembolization and enhance patient care through innovation and collaboration.
Indexed as
Identifiers
42627577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.